Erratum: Ranibizumab for the treatment of wet AMD: a summary of real-world studies

被引：0

作者：

V Chong

机构：

来源：

Eye | 2016年 / 30卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Correction to: Eye (2016) 30, 270–286; doi:10.1038/eye.2015.217; published online 4 December 2015 This article was originally published under a standard License to Publish, but has now been made available under a CC BY 4.0 license. The PDF and HTML versions of the paper have been modified accordingly.

引用

页码：1526 / 1526

共 50 条

[41] Real-World Use of Off-Label MVASI in the Treatment of Patients With Neovascular AMD and DME
Lombardo, Marco
Missiroli, Filippo
Cerri, Luca
Sorge, Roberto P.
Cesareo, Massimo
Ricci, Federico
[J]. TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2024, 13 (07):
[42] Galcanezumab in the Treatment of Migraine: A Narrative Review of Real-World Studies
Dell Agnello, Grazia
Buzzoni, Carlotta
Antenori, Amalia
Torelli, Federico
Altamura, Claudia
Vernieri, Fabrizio
[J]. CLINICAL NEUROPHARMACOLOGY, 2023, 46 (06) : 220 - 228
[43] Summary of Literature on Pediatric Real-world Evidence and Effectiveness
McMahon, Ann W.
Quinto, Kenneth
Abernethy, Amy
Corrigan-Curay, Jacqueline
[J]. JAMA PEDIATRICS, 2021, 175 (10) : 1077 - +
[44] Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting
Granstam, Elisabet
Aurell, Sandra
Sjovall, Kersti
Paul, Anna
[J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2021, 259 (08) : 2085 - 2093
[45] Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting
Elisabet Granstam
Sandra Aurell
Kersti Sjövall
Anna Paul
[J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259 : 2085 - 2093
[46] Comment on 'Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab'
Vallance, J. H.
[J]. EYE, 2012, 26 (01) : 167 - 167
[47] Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study
Hamilton, Robin D.
Clemens, Andreas
Minnella, Angelo Maria
Lai, Timothy Y. Y.
Dai, Hong
Sakamoto, Taiji
Cheung, Chui Ming Gemmy
Ngah, Nor Fariza
Dunger-Baldauf, Cornelia
Holz, Frank G.
[J]. PLOS ONE, 2020, 15 (01):
[48] Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema
Konidaris, V. E.
Tsaousis, K. T.
Al-Hubeshy, Z.
Pieri, K.
Deane, J.
Empeslidis, T.
[J]. EYE, 2017, 31 (11) : 1629 - 1630
[49] Real-world experiences with intravitreal treatment with ranibizumab and aflibercept for diabetic macular oedema 2008-2021
Lindboe, Johanne Bjerre
Brynskov, Troels
Sorensen, Torben Lykke
Laugesen, Caroline Schmidt
[J]. ACTA OPHTHALMOLOGICA, 2024, 102 (04) : e661 - e662
[50] METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Kim, Leah N.
Mehta, Hemal
Barthelmes, Daniel
Vuong Nguyen
Gillies, Mark C.
[J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (08): : 1418 - 1431

← 1 2 3 4 5 →